Abstract:Activation of the cholecystokinin type B receptor (CCKBR) by cholecystokinin octapeptide (CCK-8) inhibits opioid analgesia. Chronic opiate treatment leads to an increase in the CCK-8 concentration and thus enhances the antagonism of CCK-8 against opioid analgesia; the underlying molecular mechanisms remain of great interest. In the present study, we validated the colocalization of the μ-opioid receptor (MOR) and CCKBR in pain signal transmission-related spinal cord dorsal horn and dorsal root ganglion neurons of rats. Co-immunoprecipitation (Co-IP) and fluorescence lifetime-imaging-microscopy-based fluorescence resonance energy transfer (FLIM-FRET) assays showed that MOR heteromerized with CCKBR directly in transfected HEK293 cells. Combined with MOR mutant construction, the third transmembrane domain of MOR (TM3MOR) was demonstrated to participate in heteromerization with CCKBR. Receptor ligand binding, ERK phosphorylation and cAMP assays showed that MOR heteromerization with CCKBR weakened the activity of MOR. A cell-penetrating interfering peptide consisting of TM3MOR and TAT (a transactivator of HIV-1) sequences from the N terminal to the C terminal disrupted the MOR–CCKBR interaction and restored the activity of MOR in transfected HEK293 cells. Furthermore, intrathecal application of the TM3MOR-TAT peptide alleviated CCK-8-injection-induced antagonism to morphine analgesia in rats. These results suggest a new molecular mechanism for CCK-8 antagonism to opioid analgesia in terms of G-protein-coupled receptor (GPCR) interaction through direct heteromerization. Our study may provide a potential strategy for pain management with opioid analgesics. A hormone known to weaken the pain-relieving effects of opioid drugs does so because of interaction between the hormone receptor and the opioid receptor. A team from Peking University in Beijing, China, led by Li Su and You Wan showed that an opioid receptor and a receptor that is activated by a peptide hormone involved in digestion are both found in rat neurons of the spinal cord and spinal ganglion. They demonstrated in human cells that the two receptors could form a single structural complex, and that this process weakened the ability of the opioid receptor to respond to drugs such as morphine. A decoy peptide that disrupted the interaction between the receptors boosted the analgesic effects of morphine in rats. Similar strategies could help with pain management.

CCK-8 Reverses the Inhibitory Effect of #Kappa#-Opioid Receptor Agonist U50488H on Calcium Current in Rat Dorsal Root Ganglion Neuron

Cholecystokinin octapeptide antagonized the effect of NDAP on CaM in rat dorsal spinal synaptosome

[The Study of Effects and Mechanism of U50, 488H on Electrical Coupling During Ischemia in the Perfused Isolated Rat Heart].

Chronic U50,488h Abolishes Inositol 1,4,5-Trisphosphate and Intracellular Ca2+ Elevations Evoked by Kappa-Opioid Receptor in Rat Myocytes

Modification by Cholecystokinin Octapeptide of the Binding of?-, ?-, and <sub>K</sub>-Opioid Receptors

Ofq Reverses the Kappa-Opioid Receptor-Mediated Depression of Calcium Current in Rat Dorsal Root Ganglion Neurons

Cholecystokinin Octapeptide Antagonized Opioid Analgesia Mediated by Μ- and Κ- but Not Δ-Receptors in the Spinal Cord of the Rat

ANTAGONISTIC EFFECT OF CCK-8 ON MORPHINE-INHIBITED ELECTRICAL AND CONTRACTILE ACTIVITIES OF RAT JEJUNUM IN VITRO

Antagonism of the Suppressive Effect of Morphine on Rat Brain Synaptosomal ~(45)ca Uptake by Cholecystokinin Octapeptide

Involvement of opioid receptors in the CGRP8-37-induced inhibition of the activity of wide-dynamic-range neurons in the spinal dorsal horn of rats.

Cholecystokinin Octapeptide (CCK-8) Antagonizes Morphine Analgesia in Nucleus Accumbens of the Rat Via the CCK-B Receptor

Cholecystokinin Octapeptide Reverses the Inhibitory Effect Induced by Electroacupuncture on C-Fiber Evoked Discharges

Cholecystokinin type B receptor-mediated inhibition of A-type K + channels enhances sensory neuronal excitability through the phosphatidylinositol 3-kinase and c-Src-dependent JNK pathway

Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous antiopioid substrates?

Effects of CCK-8 on the Reinstatement of Morphine-Induced CPP and Expression of Behavioral Sensitization in Rats

Cholecystokinin Octapeptide Induces Endogenous Opioid-Dependent Anxiolytic Effects in Morphine-Withdrawal Rats

Anti-arrhythmic Effect Mediated by Regulation of Κ-Opioid Receptor Agonist U50,488H on Cx43 is Associated with Inhibition of Calcium Channel

Heteromerization of Μ-Opioid Receptor and Cholecystokinin B Receptor Through the Third Transmembrane Domain of the Μ-Opioid Receptor Contributes to the Anti-Opioid Effects of Cholecystokinin Octapeptide

CCK-8 enhances acid-sensing ion channel currents in rat primary sensory neurons

CCKB receptor antagonist L365,260 potentiates the efficacy to and reverses chronic tolerance to electroacupuncture-induced analgesia in mice

CCK RECEPTOR ANTAGONIST L-365,260 POTENTIATED ELECTROACUPUNCTURE ANALGESIA IN WISTAR RATS BUT NOT IN AUDIOGENIC EPILEPTIC RATS